GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Non-investigational Product (IP) Study to Investigate Lung Function in Women in the Third Stage of Labour
Completed
- Conditions
- Haemorrhage
- Interventions
- Device: Inhalation profile recorder
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT02106000
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
Phase 3
Completed
- Conditions
- Pain
- Interventions
- Drug: 1% diclofenac sodium plus 0.09% mentholDrug: 3% mentholDrug: Placebo with 0.09% menthol gelDrug: 1% diclofenac sodium plus 3% menthol
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 385
- Registration Number
- NCT02100670
- Locations
- 🇩🇪
PAREXEL International - Sites in Germany, Berlin, Germany
🇩🇪PAREXEL International, LLC, Berlin, Germany
🇩🇪pro scientia med im MARE Klinikum, Kiel, Germany
Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT02100644
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
Phase 3
Withdrawn
- Conditions
- Infections, Papillomavirus
- Interventions
- Procedure: Blood sampling
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2015-07-20
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02100618
Boostrix® Pregnancy Registry
Completed
- Conditions
- Pertussis
- Interventions
- Other: Data collection
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1517
- Registration Number
- NCT02096276
- Locations
- 🇺🇸
GSK Investigational Site, Research Triangle Park, North Carolina, United States
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
Phase 3
Completed
- Conditions
- Hepatitis BTetanusDiphtheriaHaemophilus Influenzae Type bPoliomyelitisAcellular Pertussis
- Interventions
- Biological: Infanrix hexaBiological: PediarixBiological: PentacelBiological: InfanrixBiological: ActHIBBiological: Engerix-BBiological: HiberixBiological: Prevnar13Biological: Rotarix
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 585
- Registration Number
- NCT02096263
- Locations
- 🇺🇸
GSK Investigational Site, Ellensburg, Washington, United States
A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: GSK587323Drug: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02094924
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 430
- Registration Number
- NCT02094937
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in Weight-training Adult Males
Phase 1
Completed
- Conditions
- Nutritional Status
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Whey protein and creatine supplementDietary Supplement: Whey protein only supplement
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02094781
- Locations
- 🇺🇸
GSK Investigational Site, Miami, Florida, United States
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Phase 1
Terminated
- Conditions
- NeoplasmsCancer
- Interventions
- Drug: GSK2816126
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT02082977
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath